Oncotelic Therapeutics, Inc. (OTLC)
| Market Cap | 14.44M -30.6% |
| Revenue (ttm) | 250.00K |
| Net Income | 247.50M |
| EPS | 0.56 |
| Shares Out | 457.51M |
| PE Ratio | 0.06 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 31,400 |
| Open | 0.0300 |
| Previous Close | 0.0300 |
| Day's Range | 0.0300 - 0.0300 |
| 52-Week Range | 0.0150 - 0.1100 |
| Beta | -0.24 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 18, 2026 |
About Oncotelic Therapeutics
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment of orphan oncology indications in the United States. The company develops antisense and small molecule injectable drugs for the treatment of cancer. It is also developing OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; OT-101, an antisense against TGF-β2, which is in phase 3 clinical trials for pancreatic cancer, melanoma, and glioblastoma, as well as for the treatment of various viru... [Read more]
Financial Performance
Financial StatementsNews
Oncotelic Therapeutics, Inc. to Present at the OTCQB Virtual Investor Conference on August 6th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as ...
Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle™ Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus)
AGOURA HILLS, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Nano today announced the publication of a comprehensive peer-reviewed study in Biomedicines ...
Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway
Clinical Program Advances Following Favorable Safety Review; Peer-Reviewed Publication Further Validates Deciparticle ™ Platform
Oncotelic Announces Peer-Reviewed Validation of Deciparticle™ Platform Supporting Clinical Development of Sapu003
Publication Highlights Novel Intravenous Everolimus Formulation and Demonstrates Broad Potential of Deciparticle ™ Technology for Hydrophobic Therapeutics
Oncotelic Launches AI-Powered GMP Manufacturing Services Platform at BIO International Convention 2026
Company to Showcase Integration of AI, Digital Batch Records, and Intelligent Robotics to Accelerate Pharmaceutical Manufacturing AGOURA HILLS, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Oncotelic Ther...
Oncotelic Advances AI-Powered GMP Manufacturing Services Platform for Revenue-Generating AI and Robotics Manufacturing Services
SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB: OTLC) today announced the completion of key Phase 2 objectives in its joint manufacturi...
NetworkNewsAudio Announces Audio Press Release (APR) Discussing the Exploration of Nanoparticle, Targeted Drug-Delivery Technologies
AUSTIN, Texas, June 05, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “How Advanced Drug Delivery Could Improve Existing Cancer Treatments,” featur...
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Eyeing Nanotech-Driven Delivery Systems, Pharmacokinetic Optimization to Advance Existing Oncology Therapies
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands w...
Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program
SAN DIEGO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Sapu Nano and Oncotelic Therapeutics (OTCQB:OTLC) today announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimu...
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Advancing Proprietary Solutions Focused on Nanotechnology-Enabled Drug Delivery, AI-Enhanced Biomedical Infrastructure
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands wi...
TechForce Robotics Enters Pharmaceutical Automation Market Through Initial Deployment at Oncotelic Therapeutics
Deployment of the Company's LIM-E autonomous laboratory support robot completes Phase 1 objectives under the joint development agreement and establishes a foundation for future pharmaceutical automati...
Oncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic Progress
Agoura Hills, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“Oncotelic” or the “Company”), a clinical-stage biotechnology company focused on oncology, AI-enabled...
NetworkNews Audio Announces Audio Press Release (APR) Discussing Developing Technologies Designed to Bypass BBB Limitations
AUSTIN, Texas, May 15, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportuniti...
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Responds to BBB Challenge with Next-Gen Drug-Delivery Platform
NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands wi...
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Proprietary N2B System May Offer Key to Unlocking Next-Gen Therapies
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands wi...
Oncotelic Therapeutics Announces Closing of a Strategic Monetization of Its CNS/Nasal Assets with Lunai Bioworks, Advancing Joint Development in Biodefense and Alzheimer's Disease
AGOURA HILLS, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“Oncotelic” or the “Company”), a late-stage clinical biopharmaceutical company focused on ...
Oncotelic Therapeutics Advances Toward Commercial Launch of AI-Enabled Robotics Platform Following Integration of 28 Million Scientific Abstracts
LOS ANGELES, April 30, 2026 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB: OTLC), a clinical-stage biotechnology company focused on oncology and AI-...
NetworkNews Audio Announces Audio Press Release (APR) Discussing Advancing Oncology Therapeutics, Strategic Positioning within High-Value Development Pathways
AUSTIN, Texas, April 24, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Rea...
Oncotelic Therapeutics Provides Corporate Update on Partnership Strategy
AGOURA HILLS, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, ...
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Real-World Example of Scientific Advancement Influence on Evaluation
NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands ...
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Leveraging Expertise amid Evaluation Evolution
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands w...
Oncotelic Therapeutics Reports FY 2025 Results Highlighting $249M Net Income and JV Pipeline Progress
AGOURA HILLS, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) (“Oncotelic”, the “Company” or “We”), a clinical-stage biopharmaceutical company developing drugs for...
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Strengthening Position with AI-Driven Tech in Automated Compliance Space
NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- via AINewsWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by AINewsWire ("AINW"), one of 75+ brand...
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Operates at Intersection of Life Sciences, Advanced Digital Technologies,
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- via AINewsWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by AINewsWire ("AINW"), one of 75+ brand...
Sapu Nano to Launch Deciparticle™ Platform and Present Clinical Pipeline at BIO-Europe Spring 2026
AGOURA HILLS, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), a leader in RNA-based therapeutics, announced today th...